These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 36552072)

  • 1. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.
    Rissardo JP; Caprara ALF
    Brain Sci; 2022 Nov; 12(12):. PubMed ID: 36552072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J; Szok D; Csáti A; Vécsei L
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CGRP receptor antagonists (gepants).
    Younis S; Latysheva NV; Danilov AB; Ashina M
    Handb Clin Neurol; 2024; 199():51-66. PubMed ID: 38307667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Brief Review of Gepants.
    Li D; Abreu J; Tepper SJ
    Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Generation Gepants: Migraine Acute and Preventive Medications.
    Moreno-Ajona D; Villar-Martínez MD; Goadsby PJ
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gepants - a long way to cure: a narrative review.
    Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
    Bedrin K; Ailani J; Dougherty C
    Headache; 2022 Nov; 62(10):1419-1423. PubMed ID: 36426766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focus on zavegepant: the first intranasal third-generation gepant.
    Scuteri D; Tarsitano A; Tonin P; Bagetta G; Corasaniti MT
    Pain Manag; 2022 Nov; 12(8):879-885. PubMed ID: 36189708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine.
    Argyriou AA; Mantovani E; Mitsikostas DD; Vikelis M; Tamburin S
    Expert Rev Neurother; 2022 Jun; 22(6):469-488. PubMed ID: 35707907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
    Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
    Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on gepants for the treatment of chronic migraine.
    Aoh Y; Hou TW; Yang CC; Chang CM; Chen SP; Tsai IJ; Cheng CW; Yang CP
    J Chin Med Assoc; 2024 Apr; 87(4):350-356. PubMed ID: 38349136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
    Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC
    Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventive Treatment of Migraine.
    Lipton RB
    Continuum (Minneap Minn); 2024 Apr; 30(2):364-378. PubMed ID: 38568488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world considerations for newly approved CGRP receptor antagonists in migraine care.
    Scuteri D; Tonin P; Nicotera P; Bagetta G; Corasaniti MT
    Expert Rev Neurother; 2022 Mar; 22(3):221-230. PubMed ID: 35240905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gepants for the treatment of migraine.
    Negro A; Martelletti P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study.
    Alsaadi T; Suliman R; Santos V; Al Qaisi I; Carmina P; Aldaher B; Haddad S; Bader Y
    Neurol Ther; 2024 Apr; 13(2):465-473. PubMed ID: 38361080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel synthetic treatment options for migraine.
    Negro A; Martelletti P
    Expert Opin Pharmacother; 2021 May; 22(7):907-922. PubMed ID: 33369482
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.